Do-Hyun Nam

Founder & Chief Executive Officer Aimed Bio Inc.

Seminars

Thursday 19th February 2026
Precise ADC Drug Discovery & Development From Bench to Bedside
9:30 am
  • Outlining how advanced computational methods and high-throughput screening of omics data are used to precisely identify and validate novel targets for antibody-drug conjugates, ensuring a strong scientific rationale from the outset
  • Discussing the crucial role of patient-derived xenografts and patient-derived organoids in evaluating ADC efficacy and safety
  • Detailing the process of translating a successful ADC candidate into a clinical setting
Do-Hyun Nam, speaking at 7th Glioblastoma Drug Development Summit